...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >High Posttransplant Cancer Incidence in Renal Transplanted Patients With Pretransplant Cancer
【24h】

High Posttransplant Cancer Incidence in Renal Transplanted Patients With Pretransplant Cancer

机译:肾移植患者的预甲醛癌症发病率高

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background. Patients with previous cancer have increasingly been accepted for renal transplantation. Posttransplant cancer risk and survival rates of these patients are unknown. Our objective was to assess the risk of posttransplant cancer in this patient group. Methods. In this retrospective, nested case-control study, we assessed the outcome of all (n = 95) renal transplanted patients with pretransplant cancer diagnoses in the Uppsala-Orebro region, Sweden. The control group was obtained from the Collaborative Transplant Study registry and included European patients without pretransplant cancer. The other control group comprised the entire renal transplanted population in Uppsala. Development of recurrent cancer, de novo cancer, and patient survival were determined. Results. Patients with pretransplant cancer showed higher incidence of posttransplant cancers and shorter survival compared with the control groups (P < 0.001). No obvious pattern in malignant diagnoses was observed. Death-censored graft survival was unaffected. Conclusions. Despite previously adequate cancer treatments and favorable prognoses, almost half of the patients experienced a posttransplant cancer. These observations do not justify abstaining from transplanting all patients with previous malignancies, because more than 50% of the patients survive 10 years posttransplantation. A careful oncological surveillance pretransplant as well as posttransplant is recommended.
机译:背景。患有先前癌症的患者越来越多地被接受肾移植。这些患者的后移植癌症风险和生存率是未知的。我们的目标是评估该患者组中患有后翻膜癌症的风险。方法。在这项回顾性的嵌套病例对照研究中,我们评估了所有(n = 95)肾移植患者在瑞典乌普萨拉 - 奥布鲁地区的预留癌症诊断的所有(n = 95)肾移植患者的结果。对照组是从协同移植研究登记处获得的,并包括欧洲没有预体癌的患者。另一个对照组包含乌普萨拉的整个肾移植群。确定了经常性癌症,de novo癌症和患者存活的发展。结果。预留癌症患者显示出癌症癌的发生率较高,与对照组相比较短的存活率(P <0.001)。观察到恶性诊断中没有明显的模式。死亡丧情的移植物生存率不受影响。结论。尽管以前充足的癌症治疗和良好的预期,但近一半的患者经历过癌症癌症。这些观察结果不仅仅是弃权移植所有患有以前恶性肿瘤的患者,因为超过50%的患者发生了10年后持续化。建议使用仔细的肿瘤监测预防植物以及后翻版物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号